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Nuclear accumulationsforming growth factor (TGF)-β signaling by retinoids occurs on a long-term
timescale, secondary to transcriptional events. Studies by our group show loss of retinoid X receptor (RXR)
alpha results in increased TGFβ2 in the midgestational heart, which may play a role in the cardiac defects
seen in this model [S.W. Kubalak, D.R. Hutson, K.K. Scott and R.A. Shannon, Elevated transforming growth
factor beta2 enhances apoptosis and contributes to abnormal outﬂow tract and aortic sac development in
retinoic X receptor alpha knockout embryos, Development 129 (2002) 733–746.]. Acute and direct
interactions between retinoid and TGFβ signaling, however, are not clearly understood. Treatment of
dispersed hearts and NIH3T3 cells for 1 h with TGFβ and retinoids (dual treatment) resulted in increased
phosphorylated Smad2 and Smad3 when compared to treatment with TGFβ alone. Of all dual treatments,
those with the RXR agonist Bexarotene, resulted in the highest level of phosphorylated Smad2, a 7-fold
increase over TGFβ2 alone. Additionally, during dual treatment phosphorylation of Smad2 occurs via the
TGFβ type I receptor but not by increased activation of the receptor. As loss of RXRα results in increased
levels of Smad2 phosphorylation in response to TGFβ treatment and since nuclear accumulation of
phosphorylated Smad2 is decreased during dual treatment, we propose that RXRα directly regulates the
activities of Smad2. These data show retinoid signaling inﬂuences the TGFβ pathway in an acute and direct
manner that has been unappreciated until now.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionTGFβ is a pleiotropic cytokinewhich affects cell growth, differentia-
tion, apoptosis, immune modulation and epithelial to mesenchymal
transformation [2]. With or without the assistance of the TGFβ type III
receptor (TβRIII) [3] TGFβ isoformsbind to the constitutivelyactive type
II receptor (TβRII) promoting its heterodimerizationwith andactivation
of the type I receptor (TβRI) [4]. TβRI then acts as a serine/threonine
kinase that phosphorylates the C-terminal SXS motif of the most
immediate downstream signal, TGFβ-activated receptor Smads, Smad2
and Smad3 (Smad2/3) [4]. Smad2/3 can be phosphorylated at alternate
motifs by other kinases outside of the canonical TGFβ signaling scheme
[5] modifying the downstream events normally ascribed to TGFβ-
mediated Smad signaling [6]. Once phosphorylated by TβRI, Smad2/3
heterodimerize with Smad4, i.e. the common Smad, aptly named
because it is common to both the TGFβ and bone morphogenetic
protein (BMP) pathways [4]. The Smad4/Smad2/3 complex then
accumulates in the nucleus [7] where it interacts with co-activators
and -repressors to regulate the transcription of speciﬁc target genes [8].l rights reserved.There are several points of control between TGFβ binding its
receptor and affecting downstream transcriptional targets. SARA, the
Smad anchor for receptor activation, regulates the subcellular
localization of Smad2 and its availability to the kinase action of TβRI
[9]. The inhibitory Smads, Smad6 and Smad7, block receptor Smad
phosphorylation via competitive inhibition at the level of the receptor
[10]. The expression of Smad7 is positively regulated by activation of
the canonical TGFβ cascade and therefore serves as a negative
feedback mechanism to blunt TGFβ signaling [11]. Smurfs, Smad-
ubiquitin regulatory factors, are E3 ligases that mediate Smad and
TGFβ receptor ubiquitination and proteasomal degradation. Smurf2
has been shown to ubiquitinate newly activated Smad2 that has
accumulated in the nucleus [12]. Smurfs also interact with Smad7 to
regulate ubiquitination and proteasomal degradation of TβRI [13].
Once activated and in the nucleus, the transcriptional effects of
TGFβ-activated receptor Smads can be blunted by binding the
transcriptional co-repressors Ski and Sno [14]. Additionally, the
phosphatase activity of protein phosphatase 1A (PPM1A) is known
to regulate the duration of TGFβ's transcriptional effects by decreasing
the amount of SXS-motif-phosphorylated Smad2 (pSmad2) in the
nucleus [15].
The retinoid derivatives of vitamin A show their own canonical
signaling cascade, which ultimately regulates developmental
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vitamin A and act as the ligands which agonize retinoid receptors
promoting their nuclear import [16], dimerization, and transcriptional
effects [17–19]. Retinoid receptor hetero- (RXR/RAR) or homo- (RXR/
RXR) dimers bind to retinoic acid response elements (RARE) or
retinoid X response elements (RXRE), respectively, within the
promoter regions of retinoid target genes such as Hox family
members, the metabolic regulator phosphoenolpyruvate carboxyki-
nase, and retinoid receptors themselves [20]. As such, retinoid
receptors are transcriptional regulators, however, there is evidence
to suggest that they serve additional purposes in the cell. It is known
that retinoid signaling can affect TGFβ signaling at the level of the
receptor Smads. Cao et al. proposed that all-trans retinoic acid (atRA)
mediates the activity of an unidentiﬁed Smad2 phosphatase leading to
lower levels of activated Smad2 [21]. It is unclear if this purported
phosphatase and PPM1A are one and the same. It has also been
reported that antagonist-treated and therefore unliganded RAR binds
Smad3 and increases Smad3-driven transcription [22]. Additionally
the transcriptional corepressor TGFβ-induced factor homeobox (TGIF)
has been shown to regulate Smad2- and RXR-driven transcriptionFig. 1. Retinoids, in the presence of TGFβ2, increase pSmad2 levels above those seen after a
20 ng/ml of TGFβ2 in the absence (closed circles) or presence (open circles) of 75 nM 9-c
densitometrically normalized to β-tubulin. The 1.0 ng/ml TGFβ2 treatments were averaged
point. Results are mean±one S.E. (B) NIH3T3 cells were treated for 1 h with varying concent
concentration ranges: atRA — 10 nM, 50 nM, 100 nM, 400 nM; Bexarotene— 25 nM, 100 nM,
subjected to Western blot and pSmad2 levels were normalized to β-tubulin. To demonstra
TGFβ2 treatment were assigned a value of one. (C) NIH3T3 cells were treated with diluent
were detected using Western blot. To demonstrate relative differences between treatments,
of one. Results are one S.E. of the mean. ⁎ indicates a p-value of .002 between control and T
groups. (D) NIH3T3 cells were treated for 5 min, 1 h, 6 h and 24 h with 3 ng/ml TGFβ2 in th
proteins were subjected to Western blot. Phosphorylated Smad2 levels were normalized to β
time course of three separate experiments is shown.[22,23]. During high levels of TGFβ signaling indicated by increased
nuclear pSmad2, TGIF binds the Smads and prevents their interaction
with transcriptional co-activators CBP and p300, effectively blunting
Smad-mediated transcription [24,25]. Under conditions of decreased
nuclear pSmad2, however, TGIF binds RXREs, blocking the transcrip-
tional activity of RXR homodimers [26].
Clearly there is growing evidence that TGFβ and retinoid pathways
reciprocally regulate each other on a long-term time scale secondary
to transcriptional and translational changes. Our ﬁndings herein
represent the ﬁrst report examining the acute effect of retinoids on
TGFβ-activated receptor Smad phosphorylation and nuclear
accumulation.
2. Materials and methods
2.1. Cell lines and treatments
NIH3T3 cells were obtained from ATCC and maintained according
to supplier's recommendations. RXRα knockout (RXRα−/−) and
matched wild type littermate mouse embryonic ﬁbroblasts (MEFs)one-hour treatment with TGFβ2 alone. (A) NIH3T3 cells were treated for 1 h with 0.1–
isRA. Total cellular proteins were subjected to Western blot and pSmad2 levels were
and assigned a value of one and all other values were further normalized to this data
rations of three retinoid species in the absence or presence of 3 ng/ml TGFβ2. Retinoid
200 nM, 400 nM; 9-cisRA — 10 nM, 25 nM, 75 nM, 400 nM. Total cellular proteins were
te relative differences between treatments, normalized pSmad2 levels obtained from
, 3 ng/ml TGFβ2, 75 nM 9-cisRA or both for 1 h. Phosphorylated Smad2 and β-tubulin
pSmad2 normalized to β-tubulin obtained from TGFβ2 treatment was assigned a value
GFβ2 groups. ⁎⁎ Represents a p-value of .001 between TGFβ2 and TGFβ2 plus 9-cisRA
e absence (closed circles) or presence (open circles) of 75 nM 9-cisRA and total cellular
-tubulin, and further normalized to the one-hour TGFβ2 treatment. One representative
Fig. 2. Phosphorylation of Smad2 SXS motif occurs solely via TβRI during co-treatment
with TGFβ2 and 9-cisRA. (A) NIH3T3 cells were pretreated for 30 min with 0, 1.0 or
10 μM of TβRI inhibitor (SB431542) prior to addition of 3 ng/ml TGFβ2 in the absence or
presence of 75 nM 9-cisRA. Total cellular proteins were subjected to Western blot and
pSmad2 levels were normalized to β-tubulin levels using densitometry values obtained
from Image J Software. For further normalization, TGFβ2 treatment in the absence of
inhibitor was assigned a value of 1. (B) TβRI was immunoprecipitated from membrane
fraction enriched proteins of NIH3T3 cells treated with diluent (Lane 2), 3 ng/ml TGFβ2
(Lane 3), 75 nM 9-cisRA (Lane 4) or both (Lane 5) for 1 h. Lane 1 shows quiescent NIH3T3
cells that have experienced no media change. Phosphorylation of TβRI was detected
using HRP-conjugated anti-phospho-threonine primary antibody (P-Thr). (C) Densito-
metry values obtained from Image J Software were used to normalize phosphorylated
TβR1 levels to IgG. Diluent treatment was assigned an arbitrary value of 1.0 and results
are shown as one S.E. of the mean.
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matings and maintained as previously described [27]. Embryonic tails
were genotyped as described [1]. For dispersed heart cultures, hearts
minus atria were dissected from E12.5 embryos. Hearts were placed in
0.05% trypsin EDTA (Gibco) and incubated at 37 °C with gentle
trituration every 2 min until minimal intact tissue remained,
approximately 6 min total. Dispersed heart media (DMEM+10% rat
serum)was added to themixture at a 1:1 concentration and cells were
pelleted via centrifugation (200 ×g for 5 min). Supernatant was
removed and pellets were resuspended in 100 μl of media per heart
followed bymicromass plating in 35mm cell culture dishes (Corning).
Cultures were maintained at 37 °C, 5% CO2. Twelve hours later, 900 μl
of mediawas added to each dish and cells were allowed to incubate for
an additional 60 h. For one-hour treatments, 300,000 MEFs or NIH3T3
cells were plated in 35 mm dishes 24 h prior to use. All cells and
dispersed hearts were serum starved for 2 h before addition of atRA
(Sigma), 9-cis-retinoic acid (9-cisRA) (Sigma), Bexarotene (Toronto
Chemical Company), TGFβ1 and TGFβ2 (R&D). Retinoids were diluted
in DMSO (Sigma) and TGFβ isoforms were diluted in 4 mM HCl with
0.1% bovine serum albumin (BSA). All “diluent” (i.e. control)
treatments received appropriate volumes of DMSO and TGFβ diluent.
For TβRI kinase inhibition, cells were serum starved prior to addition
of SB431452 reconstituted in DMSO. Cells were incubated for 30 min
with inhibitor prior to addition of TGFβ and retinoids.
2.2. Immunoblotting
Rabbit anti-phosphorylated Smad2 (Ser465/467, cat. #3108),
mouse anti-Smad2 (#3103), rabbit anti-phosphorylated Smad2
(Ser245/250/255, #3108), rabbit anti-phosphorylated Smad3
(Ser425/425, #9520) and rabbit anti-Histone H3 (#9175) were
obtained from Cell Signaling Technologies; mouse anti-β-tubulin
(Accurate Chemical Company) and HRP-conjugated-anti-phosphory-
lated threonine (Santa Cruz Biotechnology) were used for Western
blotting. Total proteins were harvested using a standard RIPA buffer
(20 mM Tris pH 7.5, 100 mM NaCl, 0.5% NP-40, 0.5 mM EDTA, 0.5 mM
PMSF) containing protease inhibitors (Complete Mini, Roche, Palo
Alto, CA) or fractionated with the Ne-Per Cytoplasmic Nuclear
Extraction Kit according to manufacturers recommendations (Pierce).
Equal volumes were boiled with denaturing loading buffer (200 mM
Tris–HCl pH 6.8, 50% Glycerol, 8% SDS, 400 mM DTT, 0.4% Bromophe-
nol Blue) and run on a 10% denaturing polyacrylamide gel for 120 min
at 130 V. Membrane protein enrichment for TβRI analysis was
accomplished with a two-step RIPA protocol. Brieﬂy, for step one,
cells were lysed in RIPA, pelleted via centrifugation and the super-
natant was reserved. For step two, the resulting pellet was
resuspended in RIPA and subject to constant gentle rocking at 4 °C
for 1 h with 10 s of maximum speed vortexing every 10min. Following
centrifugation the supernatants from step one and two were
combined and utilized for further assays.
2.3. Immunocytochemistry
Five thousand NIH3T3 cells were seeded into 4-well chamber
slides (Lab-Tek) and incubated overnight. Cells were serum starved for
2 h prior to a one-hour treatment with diluent or combinations of
3 ng/ml TGFβ2 and 75 nM 9-cisRA. Total Smad2 immunolocalization
was performed using total Smad2 antibody (Cell Signaling Technol-
ogies # 3122) according to the manufacturer's suggested protocol.
Anti-rabbit Alexa Fluor® 488 secondary antibody (Invitrogen) was
applied at a concentration of 1:100 prior to coverslipping. Photo-
graphic documentation was performed with a Leica TCS SP2 AOBS
confocal microscope. Relative nuclear Smad2 localization was deter-
mined by maintaining constant laser/gain settings throughout
microscopic documentation and by counting nuclear pixel density
using ImageJ software (freeware).2.4. Immunoprecipitation of TβRI
Twenty microliters of agarose-conjugated rabbit anti-TβRI (Santa
Cruz Biotechnology) was incubated overnight at 4 °C with 500 μg of
membrane-enriched proteins harvested from treated or untreated
NIH3T3 cells. Agarose beads plus bait and prey proteins were
pelleted, washed four times in RIPA buffer and resuspended in 2×
denaturing loading buffer. SDS PAGE was performed as described
above.
2.5. Luciferase assay
Mink lung epithelial cells (MLEC) stably transfected with a PAI-1-
luciferase reporter construct were obtained from Dr. Daniel Rifkin and
were maintained as previously described [28]. In 96-well format,
Fig. 3. Loss of RXRα leads to increased TGFβ2 mediated-Smad2 phosphorylation. (A)
Wild type (+/+) and RXRα−/− (−/−) MEFs were treated for 1 hwith 3 ng/ml TGFβ2, 75 nM
9-cisRA or both. Total cellular proteins were subjected to Western blot analysis and
pSmad2 levels were densitometrically normalized to β-tubulin. Treatment of wild type
cells with TGFβ2 alone was assigned a value of one for further normalization. (B) Wild
type (+/+) and RXRα−/− (−/−) dispersed whole hearts were treated for 1 h with 3 ng/ml
TGFβ2. Total cellular proteins were subjected to Western blot analysis and pSmad2
levels were normalized to β-tubulin levels using densitometry values obtained from
Image J Software. To demonstrate relative differences between genotypes, normalized
pSmad2 levels obtained from treatments of wild type hearts were assigned a mean
value of one. Results are shown as one S.E. of the mean.
Fig. 4. Retinoid ligands blunt Smad2-nuclear accumulation and transcriptional activity.
(A) MLEC cells harboring the PAI-1-luciferase construct were used to infer levels of
TGFβ-activated receptor Smad-driven transcription in the absence and presence of
retinoids. Cells were treated with indicated treatments for one (light bars) or 7 h (dark
bars), washed and assayed for luciferase levels 7 h after initiation of treatment. Results
show one S.E. of mean. (B) NIH3T3 cells were treated for 1 h with diluent, 3 ng/ml
TGFβ2, 75 nM 9-cisRA, or both. Cytoplasmic (C) and nuclear (N) proteins were enriched
and subjected to Western blot. Histone H3 and β-tubulin were utilized as nuclear and
cytoplasmic loading controls, respectively.
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prior to use and treated for either 1 or 7 h with combinations of TGFβ
(3 ng/ml) and retinoids (75 nM). Following the one-hour treatment,
the cells were washed with PBS and incubated for an additional 6 h in
testmedia. Treatments were executed in triplicate and luciferase assay
was performed using Bright Glo reagent (Promega) according to the
manufacturer's suggested protocol. Luciferase levels were obtained by
30-second well readings on a 96-well format luminometer (Perkin-
Elmer).
2.6. Densitometry
Immunoblot band intensities were determined using ImageJ soft-
ware and pSmad levels were normalized to β-tubulin levels. β-tubulin
was utilized as a loading control for densitometry and was considered
more appropriate than total Smad2 as dephosphorylated Smad2
undergoes TGFβ-activated proteasomal degradation [12]. This degra-
dation occurs rapidly in response to TGFβ and can affect the apparent
levels of total Smad2 (Supplemental Figure 1 and [12]).β-tubulin levels
were not affected by a one-hour treatment with the ligands used in
these studies (Supplemental Figure 1).2.7. Statistics
Parametric or non-parametric statistical tests were performed
using SPSS software when appropriate. Statistical signiﬁcance was
assumed at a p-value= .05. For non-quantiﬁed experiments, repre-
sentative data from aminimum of three independent trials are shown.
3. Results
3.1. One-hour co-treatment with TGFβ and retinoids enhances pSmad2
accumulation compared to treatment with TGFβ alone
While it is known that downstream interactions between TGFβ and
retinoid signaling pathways exist, it is unknown if they affect each other
on an acute timescale. To explore potential acute interactions between
TGFβ and retinoids we treated NIH3T3, MEFs and dispersed heart cells
for 1 h with combinations of TGFβ1 or TGFβ2 and retinoid isoforms of
varying receptor afﬁnities [29] and determined the levels of subsequent
Smad2 and Smad3 phosphorylation. A one-hour time point was chosen
because, as previously reported, a one-hour treatment with TGFβ alone
results in maximum accumulation of phosphorylated Smad2 from the
undetectable levels seen at time zero [12]. Concentration–response
studieswith varying TGFβ2 concentrations in the absence or presence of
75 nM9-cisRA resulted inmaximumSmad2 phosphorylation at 3 ng/ml
TGFβ2 (Fig.1A). Phosphorylated Smad3 levels were similarly affected as
a result of dual treatment (data not shown). Likewise, treatment with
varying concentrations of 9-cis- or atRA combined with 3 ng/ml TGFβ2
altered the Smad2 phosphorylation proﬁle in a manner that was
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concentrations of 9-cis- or atRA combined with TGFβ2 (3 ng/ml),
pSmad2 levels were nearly three fold increased over those seen with
TGFβ2 treatment alone (Fig. 1C). A similar Smad2 phosphorylation
proﬁle was observed using TGFβ1 in concert with 9-cisRA (data not
shown). Dual treatment with the RXR speciﬁc ligand, Bexarotene, in a
concentration range which solely targets RXR resulted in a seven-fold
increase in pSmad2 levels over those seen after treating with TGFβ2
alone (Fig. 1B). Additionally, time course experiments showed that
TGFβ2 treatment results in a peak level of pSmad2 at one-hour
posttreatment followed by a return toward basal levels 24 h later (Fig.
1D). Adding retinoids to the TGFβ2 treatment results in higher levels of
pSmad2, which remain elevated at 24-hour posttreatment (Fig. 1D)
demonstrating that retinoids not only potentiate the phosphorylation of
Smad2 but also affect the dynamics of its dephosphorylation. Lastly,
phosphorylation of the Smad2 linker domain was not affected by any
combination of TGFβ or retinoid treatment (Supplemental Figure 2 and
data not shown) demonstrating that this potentiated phosphorylation
effect is speciﬁc to the SXS motif of Smad2.Fig. 5. During TGFβ2 treatment, Smad2 shows less nuclear localization in the presence of ret
TGFβ2, and (D) a combination of 3 ng/ml TGFβ2 plus 75 nM 9-cisRA. Immunocytochemistry o
(E) Densitometry of nuclear regions was performed using Image J software and average nucle
of 0.001 between RA and diluent. ⁎⁎ Represents a p-value of 0.0001 between TGFβ2 and eithe
treatments.3.2. Phosphorylation of Smad2 during dual treatments occurs via TβRI
To begin to investigate the mechanism of the potentiation of
Smad2 phosphorylation in the presence of TGFβ and retinoids,
NIH3T3 cells were pretreated with SB431542, a speciﬁc and potent
inhibitor of TGFβ-induced phosphorylation of Smad2 which acts on
TβRI [30]. With inhibitor present, cells were treated for 1 h with
TGFβ2 alone or in combinationwith 9-cisRA followed byWestern blot
analysis of pSmad2 levels. Loss of Smad2 phosphorylationwas seen in
a SB431542 dose-dependent manner for both TGFβ2 and TGFβ2 plus
9-cisRA treated cells (Fig. 2A). These data show that all phosphoryla-
tion of Smad2 occurs via action of TβRI regardless of the presence of
retinoids and importantly rules out the action of alternate kinases. We
next asked if retinoids in the presence of TGFβ lead to increased
activity of TβRI as assessed by detecting phosphorylation of
threonines within TβRI itself. NIH3T3 cells were treated with
combinations of 9-cisRA and TGFβ2 for 1 h and membrane proteins
were extracted. Immunoprecipitation of TβRI was performed followed
by Western blot using HRP-conjugated anti-threonine antibodies. Ininoids. (A) NIH3T3 cells were treated for 1 h with diluent, (B) 75 nM 9-cisRA, (C) 3ng/ml
f Smad2was performed and subcellular localization determined by confocal microscopy.
ar pixel intensity is shown. Error bars denote one S.E. of themean. ⁎ Represents a p-value
r diluent or RA. ⁎⁎⁎ Represents a p-value of 0.0001 between TGFβ2 plus RA and all other
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(no media change) show no detectable basal levels of TβRI threonine
phosphorylation (Fig. 2B Lane 1) whereas a one-hour treatment with
ligands resulted in TβRI phosphorylation (Fig. 2B Lanes 3–5).
Phosphorylation in response to TGFβ (Lane 3) was increased above
that seen for diluent treatment (Lane 2). Densitometric analysis
showed that treatment with 9-cisRA plus TGFβ2 did not result in
statistically signiﬁcant elevation (p= .151) of phospho-threonine levels
compared to levels seen with TGFβ treatment alone (Fig. 2C)
suggesting that increased activity of the type I receptor is not the
mechanism by which pSmad2 is elevated during co-treatment with
TGFβ and retinoids.
Interestingly, our results showed that the act of changing media
can result in a detectable level of phosphorylation of the TβRI and
though beyond the scope of this study, we suspect that shear ﬂuid
stress may play a role in this effect. A 2004 article by Morgera et al.,
described that adding ﬂuid shear stress in the presence of high glucose
media (which is utilized in our experiments) led to a “30% increase in
TGFβ release compared to glucose stress alone” in a mesothelial cell
model [33]. This released TGFβ could act in an autocrine manner
causing some phosphorylation of the TβRI.
3.3. MEFs and dispersed hearts from RXRα−/− embryos show increased
pSmad2 following treatment with TGFβ2 in the absence of added
retinoids
In order to determine the potential role of RXRα in TGFβ2-
mediated Smad2 phosphorylation, wild type and RXRα−/− MEFs and
dispersed heart cells were generated from E12.5 mice. Cells wereFig. 6. Schematic of working hypothesis by which retinoid signaling via RXRαmay directly r
by TβRI upon TGFβ exposure. Retinoid receptors can directly bind receptor Smads (Box 1), cre
Smad2 binding partners that are acutely responsive to retinoids may be responsible for the
(Box 2). Smad2 nuclear accumulation is blunted in the presence of retinoids suggesting that
Likewise, in the presence of retinoids, receptor Smad-driven transcription is decreased. Thi
effects of retinoid signaling on Smad-mediated transcription (Box 4).treated for 1 h with TGFβ2 in the absence or presence of 9-cisRA and
pSmad2 levels were detected using Western blot. RXRα−/− MEFs
(Fig. 3A) and dispersed hearts (Fig. 3B) showed higher levels of
pSmad2 in response to a one-hour TGFβ2 treatment when compared
to matched wild type controls. Moreover, when cells were co-treated
with 9-cisRA and TGFβ2, pSmad2 levels were not elevated beyond
that of TGFβ2 alone (Fig. 3A) suggesting that RXRα likely plays a
direct role in controlling the levels of TGFβ2-mediated Smad2
phosphorylation in both the absence and presence of added RA.
3.4. Potentiation of Smad phosphorylation secondary to dual treatment
does not yield increased receptor Smad-driven transcription
To determine the downstream signaling potential of the increased
pSmad2/3 resulting from dual treatment versus that of treating with
TGFβ alone, we utilized MLEC cells stably transfected with PAI-1-
luciferase reporter. We treated equal numbers of cells and assayed for
luciferase production 7 h after a one- or seven-hour exposure to TGFβ
and/or retinoids. A one-hour exposure to TGFβ2 alone followed by a
washout and six-hour serum free incubation resulted in similar levels
of luciferase production as a seven-hour exposure to TGFβ2 (Fig. 4A).
This ﬁnding alone demonstrates that the downstream effect of TGFβ2
is determined rapidly, and that continual exposure to ligand is not
necessary to yield signiﬁcant transcriptional changes. Interestingly, at
seven-hour posttreatment, the one- and seven-hour dual treatments
with TGFβ2 and 9-cisRA resulted in less luciferase production than
seen after treatment with TGFβ2 alone (Fig. 4A) suggesting that
although pSmad2/3 levels are escalated by 1 h after dual treatment,
only a fraction of this pSmad pool is positively regulating transcrip-egulate Smad phosphorylation and subcellular accumulation. Smad2 is phosphorylated
ating amechanism bywhich theymay regulate Smad availability to the TβRI. Alternately
increased level of TGFβ-mediated Smad2 phosphorylation seen during dual treatments
cytoplasmically localized retinoid receptors may control Smad2 nuclear uptake (Box 3).
s effect may be secondary to decreased Smad nuclear accumulation or direct, negative
2285L.L. Hoover et al. / Biochimica et Biophysica Acta 1783 (2008) 2279–2286tion. In order to determine the mechanism by which this occurs, we
performed cytoplasmic and nuclear fractionation of NIH3T3 cells that
were treated with combinations of retinoids and TGFβ (Fig. 4B).
Consistent with the above transcription results, in cells treated solely
with TGFβ, the entire pSmad2 pool shuttles to the nucleus, whereas
with dual treatment, a proportion of the pSmad2 remains cytoplasmic.
Similarly, we found that immunocytochemistry of dual-treated
NIH3T3 cells (Fig. 5D, E) showed signiﬁcantly less nuclear Smad2
than did cells treated with TGFβ2 alone (Fig. 5C, E). These ﬁndings can
be explained by the ability of retinoid receptors to bind and sequester
Smads [22] and to act as regulators for the nuclear uptake of its
binding partners [34].
4. Discussion
Our data show that retinoids in the presence of TGFβ can
potentiate Smad2/3 phosphorylation and this potentiation is likely
not due to transcriptional events as it occurs during a one-hour
timeframe. Retinoid ligands alone had no effect on Smad2 phosphory-
lation (Fig. 1B–C) demonstrating that immediate activation of
endogenous local, latent TGFβ by retinoids is not contributing to the
elevated pSmad2 seenwith dual treatment in this system. Further, this
work suggests that retinoid signaling controls the availability of
Smad2 for phosphorylation by the TβRI as well as nuclear uptake of
pSmad2. As it is known that retinoid receptors physically interact with
Smads [22] and that unliganded RXR exists both in the cytosol and
nucleus [16], we hypothesize that unliganded RXRα sequesters a
portion of the total Smad2 pool, preventing it from being phosphory-
lated by the TβRI in the presence of TGFβ (Box 1 Fig. 6). When RXRα is
absent from the cytosol (as is the case during 9-cisRA treatment which
promotes RXRα nuclear translocation [16] or in RXRα−/− MEFs)
Smad2 is not sequestered by RXRα and proportionally more Smad2
can be phosphorylated under TGFβ stimulation (Fig. 3B). Alternately,
acute exposure to retinoids may affect other elements which bind
Smad2, such as microtubules, SARA, or connexins [9,35,36] (Box 2 Fig.
6). Reorganization of these elements at or near the TβRI could modify
the availability of Smad2 to be phosphorylated. An alternate
hypothesis supported by the literature is that liganded RXR hetero-
dimerizes with the vitamin D receptor (VDR) [37] lessening known
Smad-VDR interplay thus allowing more Smads to be available for
canonical TGFβ signaling.
Our data suggest that the increased pSmad2 in dual-treated wild
type cells does not escalate downstream pSmad2-mediated events
secondary to decreased nuclear accumulation of Smad2 (Box 3 Fig. 6).
We employed a Smad binding element reporter assay and showed that
a one-hour treatment with TGFβ2 plus 9-cisRA results in less Smad2/
3-driven transcription than a treatment with TGFβ2 alone. Similar
ﬁndings were described by Cao et al., albeit after an 18-hour treatment
with TGFβ and atRA [21]. The mechanism by which retinoid receptors
control Smad nuclear accumulation is still unclear however it may be
explained by the fact that RXRα, in the presence of ligand, dimerizes
with other nuclear receptors and translocates to the nucleus to
mediate transcription thus blunting its purported shuttle function
(Figs. 4B and 5). As pSmad2 is dephosphorylated in the nucleus [15],
decreased nuclear uptake may also explain the sustained elevation of
pSmad2 levels observed over a time course with dual treatment (Fig.
1D). Alternately, in dual-treated cells it is possible that RXRα shuttles
to the nucleus and binds a portion of the nuclear pSmad2, preventing
its transcriptional activities (Box 4 Fig. 6). Co-immunoprecipitation
and live cell imaging studies utilizing ﬂuorescently-tagged Smads and
retinoid receptors are currently being undertaken to assess the extent
of subcellular co-localization of these players during TGFβ and retinoic
acid treatments.
Interactions between retinoid receptors and Smads have impor-
tant implications for RXRα null cells. In the RXRα−/− embryo we have
noted elevated levels of proteins (i.e. ﬁbronectin) [38] and events (i.e.apoptosis) [1] that are positively regulated by TGFβ. We suspect that in
addition to elevated TGFβ2 levels detected in the RXRα−/−, the loss of
RXRα-mediated negative regulation of pSmad2 driven transcription is
responsible for the upregulation of events downstream of TGFβ
signaling and possibly many of the developmental defects seen in this
mouse.
To determine the effects of Smad2 dosage in vivo, crosses between
RXRα+/− and Smad2+/− mice are currently being performed. As
decreased dosage of TGFβ2 results in a partial rescue of the cardiac
phenotype seen in the RXRα−/− [1], we hypothesize that Smad2
heterozygosity will show a similar effect on the RXRα knockout
mouse if TGFβ's effects are Smad-dependent. As TGFβ can signal
through Smad-independent pathways, it is important to determine
the role of canonical signaling during cardiac development. It is clear
that retinoids can inﬂuence canonical TGFβ signaling on a long-term
timescale dependent on transcriptional events and this study
demonstrates that retinoids directly regulate Smad activity on a
truncated timescale independent of retinoid-mediated transcription.
This effect may be particularly relevant to the rapid growth and
remodeling required by the developing embryo. Our observations
contribute to the growing list of known interactions between retinoid
and TGFβ signaling and future studies will lead us to a better
understanding of such crosstalk.
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